CompanyGraph
Cardinal Health Inc.
CAH · NYSE Arca · United States
Routes prescription drugs and its own surgical supplies daily into 60,000 hospitals, pharmacies, and clinics across all 50 states.
Cardinal Health holds separate DEA wholesale distribution licences in all 50 states, which authorise its automated warehouses to receive bulk drug shipments from manufacturers like Pfizer and Merck, sort them into facility-specific orders under lot-number tracking, and deliver daily to over 60,000 hospitals, pharmacies, and clinics. Because those same licensed delivery routes also carry Cardinal Health's own branded surgical gloves and syringes, the manufacturing business piggybacks on the distribution infrastructure rather than funding its own separate logistics network. Hospitals write Cardinal Health products into their surgical protocols and pharmacies build their replenishment schedules around the daily delivery rhythm, so switching would require requalifying every product and rebuilding a delivery cadence that no competitor currently has the route network to match. The vulnerability sits in the working capital: Cardinal Health must purchase and warehouse billions of dollars of pharmaceutical inventory under DEA custody before collecting payment, so if CMS pricing policy compresses the per-unit fees enough, financing that inventory could become economically unworkable — and the 50-state licence stack cannot simply be trimmed down to reduce the cash burden without surrendering the territory the whole business depends on.
How does this company make money?
Cardinal Health charges pharmaceutical manufacturers a per-unit fee for warehousing and delivering their drugs. It also earns a markup on the Cardinal Health-branded surgical gloves, syringes, and examination gloves it sells directly to healthcare facilities. On top of that, some hospital systems pay Cardinal Health a fee to manage their supply chains as a service.
What makes this company hard to replace?
Hospital customers have Cardinal Health-branded products — specific gloves, syringes, and other supplies — already written into their surgical protocols and supply chain management systems. Switching means going through a lengthy requalification process for every alternative product. Pharmacy customers rely on Cardinal Health's daily delivery schedule, and no competitor currently has a route network in place that could step in and match that frequency without building it from scratch.
What limits this company?
Cardinal Health has to buy and store billions of dollars worth of drugs before any hospital or pharmacy pays for them. That gap between spending and collecting is the core financial squeeze. When borrowing becomes more expensive, that squeeze tightens. And the company cannot simply drop licences in certain states to cut costs without giving up the delivery territory those licences cover.
What does this company depend on?
Cardinal Health cannot operate without its DEA wholesale drug distribution licences in all 50 states, its automated warehouse management systems for sorting and tracking orders, its temperature-controlled fleet for cold-chain pharmaceuticals, its supply agreements with manufacturers like Pfizer and Merck, and its own manufacturing facilities that produce Cardinal Health-branded medical supplies.
Who depends on this company?
CVS Health and Walgreens pharmacy chains would run out of prescription medications within days if Cardinal Health stopped delivering. Hospital systems like HCA Healthcare would face shortages of surgical supplies that would force them to delay or cancel elective procedures. Independent community pharmacies would lose access to generic drug inventory, directly disrupting patient care.
How does this company scale?
Automated warehouse picking systems and route-optimisation software can be rolled out to new distribution centres relatively cheaply as volume grows. What does not scale easily is the DEA compliance side — every new state or controlled-substance category requires its own jurisdiction-specific legal process and regulatory relationships, and none of that can be automated or rushed.
What external forces can significantly affect this company?
Changes to Medicare Part D reimbursement rates affect how much Cardinal Health's pharmacy customers can afford to spend, which flows back to demand. CMS generic drug pricing policies directly compress the fees Cardinal Health earns per unit distributed. The Drug Supply Chain Security Act's serialisation mandates impose ongoing compliance costs across the entire 60,000-facility network.
Where is this company structurally vulnerable?
The Drug Supply Chain Security Act requires Cardinal Health to track every single drug unit across all 60,000 delivery points. If complying with that serialisation requirement gets expensive enough, or if CMS cuts the fees that distributors earn on generic drugs far enough, the per-unit economics that justify running the full 50-state licence stack could collapse — and that collapse would make both the pharmaceutical distribution business and the branded manufacturing business financially unworkable at the same time.